Peiyong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peiyong Li has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Xinyuan Zhu
Shanghai Jiao Tong University
8 shared publications Xinmiao Lu
Department of Nuclear Medicine, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200025, China
7 shared publicationsMuyu Wu
Department of Nuclear Medicine, School of Medicine, Ruijin Hospital, Shanghai Jiao Tong University, Shanghai, China
5 shared publicationsNan Li
Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, 270 Dong’an Road, Shanghai 200032, China
5 shared publicationsQinghua Guan
Shanghai Jiao Tong Univ, Dept Nucl Med, Sch Med, Ruijin Hosp, Shanghai 200025, Peoples R China
4 shared publicationsRuijun Pan
Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Minimally Invasive Surgery Center, Shanghai 200025, China
4 shared publications
Latest Publications
Tunable 18 F‐Labeling of Erlotinib‐Based Small Molecule Nanodrugs for Rapid PET Imaging and Targeted Therapy
Small molecule nanodrugs (SMNs) offer unique advantages for cancer therapy, yet accurately tracking their in vivo fate without perturbing their native assembly remains challenging. Here, we report a spacer engineering strategy that enables efficient 1 8 F‐labeling while preserving SMNs self‐assembly. Erlotinib‐based amphiphilic derivatives containing oligoethylene glycol (OEG) spacers of tunable length were designed to simultaneously regulate steric hindrance for aliphatic S N 2 radiofluorination and the amphiphilic balance required for nanoparticle formation. Spacer elongation reduced steric hindrance at the labeling site and thereby improved radiochemical yields, while also enabling precise control over nanoparticle size. The optimized radiolabeled formulation, [ 18 F]E3F NPs , exhibited prolonged blood circulation and rapid tumor accumulation, enabling high‐contrast PET imaging of PANC‐1 xenografts as early as 15 min after injection. In addition, the corresponding nonradioactive formulation, E3F NPs , showed significantly improved antitumor efficacy compared with nonassembled E3F through reduced EGFR phosphorylation and increased tumor cell apoptosis. This work provides an initial evaluation that spacer engineering can coordinate radiolabeling and self‐assembly while enabling PET tracking of SMNs, supporting the development of image‐guided cancer theranostics.
Tunable 18 F‐Labeling of Erlotinib‐Based Small Molecule Nanodrugs for Rapid PET Imaging and Targeted Therapy
Small molecule nanodrugs (SMNs) offer unique advantages for cancer therapy, yet accurately tracking their in vivo fate without perturbing their native assembly remains challenging. Here, we report a spacer engineering strategy that enables efficient 1 8 F‐labeling while preserving SMNs self‐assembly. Erlotinib‐based amphiphilic derivatives containing oligoethylene glycol (OEG) spacers of tunable length were designed to simultaneously regulate steric hindrance for aliphatic S N 2 radiofluorination and the amphiphilic balance required for nanoparticle formation. Spacer elongation reduced steric hindrance at the labeling site and thereby improved radiochemical yields, while also enabling precise control over nanoparticle size. The optimized radiolabeled formulation, [ 18 F]E3F NPs , exhibited prolonged blood circulation and rapid tumor accumulation, enabling high‐contrast PET imaging of PANC‐1 xenografts as early as 15 min after injection. In addition, the corresponding nonradioactive formulation, E3F NPs , showed significantly improved antitumor efficacy compared with nonassembled E3F through reduced EGFR phosphorylation and increased tumor cell apoptosis. This work provides an initial evaluation that spacer engineering can coordinate radiolabeling and self‐assembly while enabling PET tracking of SMNs, supporting the development of image‐guided cancer theranostics.
- 3 March 2023
- Published by Springer Nature in Journal of Fluorescence
- Vol. 33 (5) , 1853-1860
Development of a H2S-responsive NIR Fluorescent Probe for H2S Detection and H2S Releasing Monitoring From Prodrug
H2S was deemed as a toxic gradient in the realm of food and environment but plays pivotal pathophysiological roles in organisms. H2S instabilities and disturbances are always responsible for multiple disorders. We fabricated a H2S-responsive NIR fluorescent probe (HT) for H2S detection and evaluation both in vitro and in vivo. HT exhibited rapid H2S response within 5 min, accompanied with visible color change and NIR fluorescence generation, and the fluorescent intensities were linearly correlated with corresponding H2S concentrations. When HT was incubated with A549 cells, the intracellular H2S and H2S fluctuations could be monitored ore rotundo via the responsive fluorescence. Meanwhile, when HT was co-administrated with H2S prodrug ADT-OH, the H2S release from ADT-OH could be visualized and monitored to evaluate its release efficacy. Graphical Abstract
- 3 March 2023
- Published by Springer Nature in Journal of Fluorescence
- Vol. 33 (5) , 1853-1860
Development of a H2S-responsive NIR Fluorescent Probe for H2S Detection and H2S Releasing Monitoring From Prodrug
H2S was deemed as a toxic gradient in the realm of food and environment but plays pivotal pathophysiological roles in organisms. H2S instabilities and disturbances are always responsible for multiple disorders. We fabricated a H2S-responsive NIR fluorescent probe (HT) for H2S detection and evaluation both in vitro and in vivo. HT exhibited rapid H2S response within 5 min, accompanied with visible color change and NIR fluorescence generation, and the fluorescent intensities were linearly correlated with corresponding H2S concentrations. When HT was incubated with A549 cells, the intracellular H2S and H2S fluctuations could be monitored ore rotundo via the responsive fluorescence. Meanwhile, when HT was co-administrated with H2S prodrug ADT-OH, the H2S release from ADT-OH could be visualized and monitored to evaluate its release efficacy. Graphical Abstract
- Open Access
- 27 January 2022
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2022, 1-11
Identification of Key Genes and Pathways Involved in Circulating Tumor Cells in Colorectal Cancer
Background. Characterization of the features associated with circulating tumor cells (CTCs) is one of major interests for predicting clinical outcome of colorectal cancer (CRC) patients. However, the molecular features of CTCs remain largely unclear. Methods. For identification of key genes and pathways, GSE31023, contained CTCs from six metastatic CRC patients and three controls, was retrieved for differentially expressed gene (DEG) analysis. Protein-protein interaction networks of DEGs were constructed. Hub genes from the network were prognostic analyzed, as well as the association with tumor-infiltrating immune cells. Results. 1353 DEGs were identified between the CTC and control groups, with 403 genes upregulated and 950 downregulated. 32 pathways were significantly enriched in KEGG, with ribosome pathway as top. The top 10 hub genes were included, including eukaryotic translation elongation factor 2 (EEF2), ribosomal protein S2 (RPS2), ribosomal protein S5 (RPS5), ribosomal protein L3 (RPL3), ribosomal protein S3 (RPS3), ribosomal protein S14 (RPS14), ribosomal protein SA (RPSA), eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), ribosomal protein S15a (RPS15A), and ribosomal protein L4 (RPL4). The correlation between CD4+ T cells and RPS14 ( ) was the highest in colon cancer while CD8+ T and RPS2 ( ) was the highest in rectal cancer. Conclusion. This study identified potential role of ribosome pathway in CTC, providing further insightful therapeutic targets and biomarkers for CRC.
- 27 January 2022
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2022, 1-11
Open AccessIdentification of Key Genes and Pathways Involved in Circulating Tumor Cells in Colorectal Cancer
Background. Characterization of the features associated with circulating tumor cells (CTCs) is one of major interests for predicting clinical outcome of colorectal cancer (CRC) patients. However, the molecular features of CTCs remain largely unclear. Methods. For identification of key genes and pathways, GSE31023, contained CTCs from six metastatic CRC patients and three controls, was retrieved for differentially expressed gene (DEG) analysis. Protein-protein interaction networks of DEGs were constructed. Hub genes from the network were prognostic analyzed, as well as the association with tumor-infiltrating immune cells. Results. 1353 DEGs were identified between the CTC and control groups, with 403 genes upregulated and 950 downregulated. 32 pathways were significantly enriched in KEGG, with ribosome pathway as top. The top 10 hub genes were included, including eukaryotic translation elongation factor 2 (EEF2), ribosomal protein S2 (RPS2), ribosomal protein S5 (RPS5), ribosomal protein L3 (RPL3), ribosomal protein S3 (RPS3), ribosomal protein S14 (RPS14), ribosomal protein SA (RPSA), eukaryotic translation elongation factor 1 alpha 1 (EEF1A1), ribosomal protein S15a (RPS15A), and ribosomal protein L4 (RPL4). The correlation between CD4+ T cells and RPS14 ( ) was the highest in colon cancer while CD8+ T and RPS2 ( ) was the highest in rectal cancer. Conclusion. This study identified potential role of ribosome pathway in CTC, providing further insightful therapeutic targets and biomarkers for CRC.
- 1 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 54, 116583
Development and preliminary evaluation of an integrin α2β1-targeted PET probe as a supplement and alternative of PSMA imaging for prostate cancer
- 1 January 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 54, 116583
Development and preliminary evaluation of an integrin α2β1-targeted PET probe as a supplement and alternative of PSMA imaging for prostate cancer
- Open Access
- 1 June 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 4567-4578
Detection and Clinical Value of Circulating Tumor Cells as an Assisted Prognostic Marker in Colorectal Cancer Patients
Background: Circulating tumor cells (CTCs) are cells that have been shed into the vasculature from a primary tumor and circulate in the bloodstream. It has been suggested that detecting CTCs could help the clinician to detect early metastasis or recurrence more effectively. This trial sets out to assess the detection and clinical value of CTCs as an assisted prognostic marker in patients with colon cancer and rectal cancer. Methods: A prospective cohort of patients with colorectal cancer (CRC) was enrolled from July 2015 to February 2018 in Shanghai Minimally Invasive Surgery Center, Shanghai, China. In this study, 149 patients with CRC were enrolled and underwent surgical treatment. There were 79 cases of colon cancer and 70 cases of rectal cancer, including 93 males and 56 females. To investigate the correlativity and clinical value of CTCs, the patients were statistically analyzed in different subgroups: colon cancer group vs rectal cancer group, and left hemicolon cancer group vs right hemicolon cancer group. Results: The results of analysis comparing CTC counts and clinical pathological features in colon and rectal cancer indicated that with increased tumor stage, the number of CTCs also increased, with significant statistical differences. CTC counts in patients with colon and rectal cancer showed positive correlations with TNM staging (P=0.001, 0.013, respectively), T staging (P=0.021, 0.001), N staging (P=0.014, 0.035) and M staging (P=0.018, 0.203). Detection of serum biomarkers in CTC-positive and CTC-negative groups indicated a significantly increasing expression in the CTC-positive group. To confirm the correlations between CTCs and histoembryological differences, analysis was conducted with the patients in two subgroups: left hemicolon cancer group and right hemicolon cancer group. The results showed that the positive rate of CTCs increased in both groups with the increase in tumor stage. The survival analysis indicated that there was a steep gradient in survival in the follow-up period, particularly in the CTC-positive group (P=0.000). Risk assessment curves showed that the change escalated more rapidly in the CTC-positive group. Furthermore, with the increase in T stage, changes in the survival curve and risk curve escalated more rapidly in the CTC-positive group. Conclusion: It was confirmed that in the left hemicolon cancer group, a much higher coincidence rate could be found on CTC-positive rate and clinicopathological features, than in the right hemicolon cancer group. The sensitivity of CTCs may be related to the histoembryological location of the tumor, lymphatic metastasis and the depth of infiltration. Monitoring CTCs may have value in evaluating clinical staging and estimating clinical prognosis.
- 1 June 2021
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 13, 4567-4578
Open AccessDetection and Clinical Value of Circulating Tumor Cells as an Assisted Prognostic Marker in Colorectal Cancer Patients
Background: Circulating tumor cells (CTCs) are cells that have been shed into the vasculature from a primary tumor and circulate in the bloodstream. It has been suggested that detecting CTCs could help the clinician to detect early metastasis or recurrence more effectively. This trial sets out to assess the detection and clinical value of CTCs as an assisted prognostic marker in patients with colon cancer and rectal cancer. Methods: A prospective cohort of patients with colorectal cancer (CRC) was enrolled from July 2015 to February 2018 in Shanghai Minimally Invasive Surgery Center, Shanghai, China. In this study, 149 patients with CRC were enrolled and underwent surgical treatment. There were 79 cases of colon cancer and 70 cases of rectal cancer, including 93 males and 56 females. To investigate the correlativity and clinical value of CTCs, the patients were statistically analyzed in different subgroups: colon cancer group vs rectal cancer group, and left hemicolon cancer group vs right hemicolon cancer group. Results: The results of analysis comparing CTC counts and clinical pathological features in colon and rectal cancer indicated that with increased tumor stage, the number of CTCs also increased, with significant statistical differences. CTC counts in patients with colon and rectal cancer showed positive correlations with TNM staging (P=0.001, 0.013, respectively), T staging (P=0.021, 0.001), N staging (P=0.014, 0.035) and M staging (P=0.018, 0.203). Detection of serum biomarkers in CTC-positive and CTC-negative groups indicated a significantly increasing expression in the CTC-positive group. To confirm the correlations between CTCs and histoembryological differences, analysis was conducted with the patients in two subgroups: left hemicolon cancer group and right hemicolon cancer group. The results showed that the positive rate of CTCs increased in both groups with the increase in tumor stage. The survival analysis indicated that there was a steep gradient in survival in the follow-up period, particularly in the CTC-positive group (P=0.000). Risk assessment curves showed that the change escalated more rapidly in the CTC-positive group. Furthermore, with the increase in T stage, changes in the survival curve and risk curve escalated more rapidly in the CTC-positive group. Conclusion: It was confirmed that in the left hemicolon cancer group, a much higher coincidence rate could be found on CTC-positive rate and clinicopathological features, than in the right hemicolon cancer group. The sensitivity of CTCs may be related to the histoembryological location of the tumor, lymphatic metastasis and the depth of infiltration. Monitoring CTCs may have value in evaluating clinical staging and estimating clinical prognosis.
- 1 March 2021
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 199, 111542
Evaluation of a new magnetic bead as an integrated platform for systematic CTC recognition, capture and clinical analysis
- 1 March 2021
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 199, 111542
Evaluation of a new magnetic bead as an integrated platform for systematic CTC recognition, capture and clinical analysis
- 1 January 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 30, 115930
Ratiometric nanoprobe for circulating tumor cell detection and intracellular hydrogen peroxide evaluation in colorectal cancer patients
- 1 January 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 30, 115930
Ratiometric nanoprobe for circulating tumor cell detection and intracellular hydrogen peroxide evaluation in colorectal cancer patients